Mark Bush

1.7k citations

59 papers · 1.4k indexed · h-index 19

Impact in

Endocrinology, Diabetes and Metabolism top 2%
- Diabetes Treatment and Management
- Diabetes Management and Research
Small Animals top 2%
- Veterinary Orthopedics and Neurology

Papers in ⓘ

Equine 3
Small Animals 10
- Veterinary Orthopedics and Neurology 9

Co-authors: Murray Stewart (5 shared papers)Fred Yang (3 shared papers)M. Claire Holland (3 shared papers)Susan Walker (2 shared papers)Robert L. Dobbins (2 shared papers)Rebecca J. Hodge (2 shared papers)Erika H. De Boever (2 shared papers)Jessica Matthews (2 shared papers)
Journals: The Journal of Clinical Pharmacology (7 papers)Veterinary and Comparative Orthopaedics and Traumatology (6 papers)Journal of Small Animal Practice (3 papers)Molecular Psychiatry (3 papers)Journal of Andrology (3 papers)
Partner nations: United States United Kingdom Japan

In The Last Decade

Mark Bush

58 papers receiving 1.3k citations

Peers

Countries citing papers authored by Mark Bush

Since Specialization

Citations

This map shows the geographic impact of Mark Bush's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Bush with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Bush more than expected).

Fields of papers citing papers by Mark Bush

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Bush. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Bush. The network helps show where Mark Bush may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Bush, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Bush Line = papers co-authored together Mark Bush links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes Diabetes Care ·Julio Rosenstock, Jane E.B. Reusch, Mark Bush, Fred Yang, Murray Stewart, (unknown)	2009	198
2	Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes The Journal of Clinical Endocrinology & Metabolism ·Jessica Matthews, Murray Stewart, Erika H. De Boever, Robert L. Dobbins, Rebecca J. Hodge, Susan Walker, M. Claire Holland, Mark Bush, (unknown)	2008	175
3	Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long‐acting glucagon‐like peptide‐1 mimetic, in healthy subjects Diabetes Obesity and Metabolism ·Mark Bush, Jessica Matthews, Erika H. De Boever, Robert L. Dobbins, Rebecca J. Hodge, Susan Walker, M. Claire Holland, Marie Gutierrez, Murray Stewart	2009	143
4	Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects Molecular Psychiatry ·Hisham Ziauddeen, Samuel R. Chamberlain, Pradeep J. Nathan, Alexa Koch, Kay Maltby, Mark Bush, Wuhai Tao, Antonella Napolitano, Andrew L Skeggs, Allison C. Brooke, Lucy G. Cheke, Nicola S. Clayton, I. Sadaf Farooqi, Stephen O’Rahilly, Dawn Waterworth, Kijoung Song, Laine Hosking, Duncan Richards, Paul C. Fletcher, Edward T. Bullmore	2012	85
5	Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans Molecular Psychiatry ·Eugenii A. Rabiner, John D. Beaver, Aidan Makwana, Graham E. Searle, Christopher J. Long, Pradeep J. Nathan, Rexford D. Newbould, James Howard, Sam R. Miller, Mark Bush, Samuel P. Hill, Richard R. Reiley, Jan Passchier, Roger N. Gunn, Paul M. Matthews, Edward T. Bullmore	2011	76
6	Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies PLoS ONE ·Derek J. Nunez, Mark Bush, David Collins, S. McMullen, Dawn Gillmor, Glen Apseloff, George Atiee, Leonor Corsino, Linda Morrow, Paul L. Feldman	2014	56
7	Opioid Receptor Modulation of Hedonic Taste Preference and Food Intake: A Single‐Dose Safety, Pharmacokinetic, and Pharmacodynamic Investigation With GSK1521498, a Novel μ‐Opioid Receptor Inverse Agonist The Journal of Clinical Pharmacology ·Pradeep J. Nathan, Barry V. O’Neill, Mark Bush, Annelize Koch, Wenli Tao, Kay Maltby, Antonella Napolitano, Allison C. Brooke, Andrew Skeggs, Craig S. Herman, Andrew L. Larkin, Diane M. Ignar, Duncan Richards, Pauline Williams, Edward T. Bullmore	2011	44
8	Pharmacokinetics and Pharmacodynamics of Recombinant FGF‐2 in a Phase I Trial in Coronary Artery Disease The Journal of Clinical Pharmacology ·Mark Bush, Emil Samara, M.J. Whitehouse, Carl Yoshizawa, Deborah L. Novicki, Marilyn C. Pike, Roger J. Laham, Michael Simons, Nicolas A.F. Chronos	2001	40
9	Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus Current Medical Research and Opinion ·Yutaka Seino, Hiromu Nakajima, Hajime Miyahara, Takashi Kurita, Mark Bush, Fred Yang, Murray Stewart, (unknown)	2009	40
10	Propagation of a partial incomplete ossification of the humeral condyle in an American cocker spaniel Journal of Small Animal Practice ·Philip Witte, Mark Bush, H. William Scott	2010	35
11	Accelerating the Drug Optimization Process: Identification, Structure Elucidation, and Quantification of in Vivo Metabolites Using Stable Isotopes with LC/MSⁿ and the Chemiluminescent Nitrogen Detector Analytical Chemistry ·Eric W. Taylor, Weiping Jia, Mark Bush, Gavin Dollinger	2002	32
12	Pharmacokinetics and Pharmacodynamics of 7-Nitroindazole, a Selective Nitric Oxide Synthase Inhibitor, in the Rat Hippocampus Pharmaceutical Research ·Mark Bush, Gary M. Pollack	2001	31
13	Effect of use of different landmark methods on determining stifle angle and on calculated tibial tuberosity advancement Veterinary and Comparative Orthopaedics and Traumatology ·(unknown), (unknown), M. R. Owen, Mark Bush	2011	27
14	A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus Current Medical Research and Opinion ·Yutaka Seino, Nobuya Inagaki, Hajime Miyahara, Inaha Okuda, Mark Bush, June Ye, M. Claire Holland, Susan Johnson, Eric Lewis, Hiromu Nakajima	2014	27
15	Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days Journal of Clinical Oncology ·Howard A. Burris, Patricia LoRusso, Suzanne F. Jones, Tina Guthrie, J. B. Orr, Daphne Williams, Jeffrey P. Hodge, Mark Bush, James H. Sabry	2004	25
16	Short‐term outcome and complications ofTPLOusing anatomically contoured locking compression plates in small/medium‐breed dogs with “excessive” tibial plateau angle Journal of Small Animal Practice ·Darren Barnes, Tonje Trinterud, M. R. Owen, Mark Bush	2016	25
17	Pharmacokinetics and protein binding of the selective neuronal nitric oxide synthase inhibitor 7‐nitroindazole Biopharmaceutics & Drug Disposition ·Mark Bush, Gary M. Pollack	2000	24
18	Effects of Multiple Doses of Albiglutide on the Pharmacokinetics, Pharmacodynamics, and Safety of Digoxin, Warfarin, or a Low-Dose Oral Contraceptive Postgraduate Medicine ·Mark Bush, Rhona Scott, Prapoch Watanalumlerd, Hui Zhi, Eric Lewis	2012	23
19	The healing of avian fractures: a histological xeroradiographic study Journal of the American Animal Hospital Association ·Mark Bush, Richard J. Montali, Gary Novak, A. Everette James	1976	22
20	Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy Cancer Chemotherapy and Pharmacology ·Araz Marachelian, Ami V. Desai, Frank M. Balis, Howard M. Katzenstein, Muna Qayed, Michael B. Armstrong, Kathleen Neville, Susan L. Cohn, Mark Bush, Rudy Gunawan, Allison Lim, Malcolm A. Smith, L. Mary Smith	2016	18

About Mark Bush

Mark Bush is a scholar working on Equine, Small Animals, Endocrinology, Diabetes and Metabolism, Rehabilitation and Aging, having authored 59 papers that have together received 1.4k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (9 papers), Veterinary Orthopedics and Neurology (9 papers), Orthopedic Surgery and Rehabilitation (8 papers), Pharmacology and Obesity Treatment (7 papers), Metabolism, Diabetes, and Cancer (6 papers), Bone fractures and treatments (5 papers), Neuropeptides and Animal Physiology (5 papers) and Hormonal and reproductive studies (5 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (599 citations), Small Animals (145 citations), Equine (24 citations), Endocrine and Autonomic Systems (89 citations) and Cellular and Molecular Neuroscience (193 citations). Mark Bush has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Murray Stewart, Fred Yang, M. Claire Holland, Susan Walker, Robert L. Dobbins, Rebecca J. Hodge, Erika H. De Boever, Jessica Matthews, Jane E.B. Reusch and Julio Rosenstock. Their work appears in journals such as The Journal of Clinical Pharmacology, Veterinary and Comparative Orthopaedics and Traumatology, Journal of Small Animal Practice, Molecular Psychiatry and Journal of Andrology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact